Frank Griscelli holds a Doctor of Pharmacy degree and a Doctor of Science degree. He is a Professor of Biotherapy at Paris University with 23 years of research experience in the realm of medical oncology and gene therapy. Since 1997, he has served as the chairman of the virology laboratory at Gustave-Roussy Institut (Villejuif). Additionally, he has taken on the responsibility of overseeing studies involving patients participating in gene therapy clinical trials in collaboration with various industrial promoters such as Transgene, Aventis, and Cobra Therapeutics. Furthermore, he played a pivotal role in establishing and advancing an insurance and quality control laboratory within the American subsidiary of Rhône Mérieux (Athens, GA, USA), specializing in the field of vaccines. Frank Griscelli is also an investigator for the preclinical studies concerning an anti-tumor immunotherapy project that employs pluripotent stem cells. His expertise extends to areas such as formulations, quality control, and the qualification of therapeutic products at iPSirius.